Search results for " onset"

showing 10 items of 418 documents

Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.

2009

Abstract Background/aim To present clinical and genetic characteristics of all Romanian patients with Gaucher disease type 1, in whom specific diagnosis has been confirmed by enzymatic and molecular methods and to analyze their outcome with and without enzymatic replacement therapy (ERT). Patients, methods There are fifty patients (F/M — 1.63/1) with Gaucher disease type 1. Clinical status, haemoglobin, thrombocytes, hepatic/splenic volume, bone mineral density and severity score were assessed at baseline and every six months thereafter. Thirty-nine patients (78%) received imiglucerase (44.4 ± 13.6 U/kg/2 weeks) for 3.1 +/− 1.4 years. Results Based on general prevalence data, our group repr…

AdultMalemedicine.medical_specialtyEvery Six MonthsBone diseaseImigluceraseAdolescentGenotypeDiseaseGastroenterologyYoung AdultInternal medicineGenotypeInternal MedicinemedicineHumansPlateletAge of OnsetChildAllelesBone mineralGaucher Diseasebusiness.industryRomaniaInfantAnemiaMiddle Agedmedicine.diseasePrognosisThrombocytopeniaSurgeryHexosaminidasesChild PreschoolMutationSplenomegalyGlucosylceramidaseFemalebusinessVisceromegalymedicine.drugEuropean journal of internal medicine
researchProduct

Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.

2019

Itch is the most bothersome symptom in psoriasis, often leading to impaired quality of life. Treatment of psoriasis-induced itch is frequently unsatisfactory as the various therapies employed have a delayed onset of effect. Histamine-1 receptor (H1) antihistamines are not recommended in treatment guidelines as histamine is not considered a key mediator in psoriasis. However, patients using H1 antihistamines frequently report benefits in questionnaire-based studies. To address these contradictions, we examined the short-term effects of levocetirizine, a nonsedating H1 antihistamine, on psoriasis-related itch and itch-related quality of life. In this pilot study, patients with psoriasis-relat…

AdultMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingTime FactorsPilot ProjectsDermatologyLevocetirizine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesPsoriasisparasitic diseasesotorhinolaryngologic diseasesMedicineEffective treatmentHumansPsoriasisskin and connective tissue diseasesH1 antihistamineDose-Response Relationship Drugbusiness.industryPruritusDelayed onsetGeneral MedicineMiddle Agedmedicine.diseaseDermatologyeye diseasesCetirizineTreatment Outcome030220 oncology & carcinogenesisConcomitantQuality of LifeFemaleOpen labelbusinessmedicine.drugDermatologic therapyREFERENCES
researchProduct

Multiple sclerosis severity score: Using disability and disease duration to rate disease severity

2005

Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. I…

AdultMalemedicine.medical_specialtyMultiple SclerosisDatabases FactualCross-sectional studyModels NeurologicalDiseaseSUSCEPTIBILITYSeverity of Illness IndexCohort StudiesDisability EvaluationPredictive Value of TestsRecurrenceSeverity of illnessmedicineHumansLongitudinal StudiesAge of OnsetModels StatisticalExpanded Disability Status Scalebusiness.industryMultiple sclerosisOUTCOME MEASUREReproducibility of ResultsNATURAL-HISTORYMiddle AgedPrognosismedicine.diseaseCross-Sectional StudiesPredictive value of testsDisease ProgressionPhysical therapyFemaleFranceNeurology (clinical)Age of onsetbusinessCohort study
researchProduct

Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series.

2012

To assess clinical features and general health status of adult patients with mucopolysaccharidosis (MPS) VI. This report includes the clinical history of patients older than 18 years with slowly progressing MPS VI and the retrospective analysis of the outcomes of available data collected between September 2003 and October 2008 at the Center of Pediatric and Adolescent Medicine, University Medical Center, Johannes Gutenberg-University of Mainz, Germany. Variables included were urinary glycosaminoglycan (uGAG) level, mutation analysis, body height, forced vital capacity (FVC), 6-minute walk test, echocardiographic findings, the need for craniocervical decompression surgery, orthopaedic findin…

AdultMalemedicine.medical_specialtyN-Acetylgalactosamine-4-SulfataseMucopolysaccharidosismedicine.medical_treatmentCarpal tunnel surgeryFEV1/FVC ratioAdolescent medicineYoung AdultValve replacementGermanyGeneticsmedicineHumansAge of OnsetCarpal tunnel syndromeGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis VIbusiness.industryMucopolysaccharidosis VIEnzyme replacement therapymedicine.diseaseSurgeryPhenotypeDisease ProgressionFemalebusinessFollow-Up StudiesJournal of inherited metabolic disease
researchProduct

BODY MASS INDEX DOES NOT CHANGE BEFORE PARKINSON'S DISEASE ONSET.

2008

Background and purpose:  Previous studies on the association between Parkinson’s disease (PD) and body mass index (BMI) have reported conflicting results. We investigated the relationship between PD and BMI by a case–control study. Methods:  PD patients were randomly matched to healthy individuals by sex and age. BMI distribution in cases has been compared with BMI of controls and odd ratios (ORs) with 95% CI were calculated. Results:  We included 318 PD patients and 318 controls. We observed no association between PD and BMI. BMI distribution in cases and controls was similar also when we adjusted for diabetes, hypercholesterolemia and the time elapsed between PD onset and the interview (O…

AdultMalemedicine.medical_specialtyParkinson's diseaseHypercholesterolemiaPopulationComorbidityWeight GainCoffeeBody Mass IndexRisk FactorsInternal medicineDiabetes mellitusWeight LossEpidemiologyDiabetes MellitusmedicineHumansObesityAge of OnseteducationAgedAged 80 and overHypertriglyceridemiaeducation.field_of_studybusiness.industrySmokingCase-control studynutritional and metabolic diseasesParkinson DiseaseMiddle AgedOverweightmedicine.diseaseNeurologyCase-Control StudiesHealthy individualsanthropometrical measures body mass index case–control study epidemiology Parkinson's disease risk factorsPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessBody mass index
researchProduct

A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study.

2015

Objective: Qualitative capillaroscopy patterns in juvenile- and adult-onset systemic sclerosis (SSc) were studied in adulthood using data from the EULAR Scleroderma Trials and Research (EUSTAR) database. Methods: Data collected between June 2004 and April 2013 were examined with focus on capillaroscopy. In this retrospective exploratory study, series of patients with juvenile-onset SSc were matched with series of adult-onset SSc having the same gender and autoantibody profile. Results: 30 of 123 patients with juvenile-onset and 2108 of 7133 with adult-onset SSc had data on capillaroscopy. Juvenile-onset SSc showed scleroderma pattern more frequently than adult-onset SSc (93.3% and 88%). The…

AdultMalemedicine.medical_specialtyPathologyAdolescentKlinikai orvostudományokBiochemistryJuvenile systemic sclerosiSclerodermaMicroscopic AngioscopySystemic sclerosiScleroderma LocalizedYoung AdultMedicineJuvenileHumansYoung adultAge of Onsetskin and connective tissue diseasesChildNailfold CapillaroscopyVideocapillaroscopyAgedRetrospective StudiesEUSTARScleroderma Systemicintegumentary systemCapillaroscopybusiness.industrySimilar distributionMicrocirculationAutoantibodyRetrospective cohort studyOrvostudományokCell BiologyMiddle Agedmedicine.diseaseDermatologyCapillariesNailfold capillaroscopyFemaleAge of onsetCardiology and Cardiovascular MedicinebusinessCapillaroscopy; EUSTAR; Juvenile systemic sclerosis; Microcirculation; Nailfold capillaroscopy; Systemic sclerosis; Videocapillaroscopy; Biochemistry; Cardiology and Cardiovascular Medicine; Cell BiologyMicrovascular research
researchProduct

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myelo…

2011

The rate of asymptomatic amyloidosis (AL) among patients with newly diagnosed multiple myeloma (MM) or smoldering multiple myeloma (SMM) is unknown. We evaluated number and clinical significance of asymptomatic AL in consecutive MM and SMM patients, not having recognition of symptomatic AL at the time of their diagnostic bone marrow biopsy. Bone marrow biopsies were stained with Congo red and considered diagnostic for AL in case of positive Congo red staining with apple-green birefringence. Biopsies from 144 patients were evaluated: 77 had a diagnosis of MM and 67 of SMM. The median age was 59 (range 26–84) years; the median follow-up was 76 months (range 0–216). Immunoglobulin isotypes wer…

AdultMalemedicine.medical_specialtyPathologyBiopsyImmunoglobulin DAsymptomaticSettore MED/15 - Malattie Del SangueImmunoglobulin Light-chain AmyloidosisBone MarrowInternal medicineBiopsyMedicineHumansAge of OnsetMultiple myelomaAgedRetrospective StudiesAged 80 and overHematologybiologymedicine.diagnostic_testbusiness.industryAmyloidosisamyloidosis multiple myelomaHematologyGeneral MedicineAmyloidosisMiddle Agedmedicine.diseasemultiple myelomamedicine.anatomical_structureAsymptomatic Diseasesbiology.proteinFemaleImmunoglobulin Light ChainsBone marrowmedicine.symptombusiness
researchProduct

Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCL…

2012

In this prospective, cross-sectional, multicenter study, we assessed clinical and laboratory characteristics from patients with cutaneous lupus erythematosus (CLE) using the Core Set Questionnaire of the European Society of Cutaneous Lupus Erythematosus (EUSCLE). 1002 (768 females, 234 males) patients with different subtypes of CLE, such as acute CLE (ACLE, 304 patients), subacute CLE (SCLE, 236 patients), chronic CLE (CCLE, 397 patients), and intermittent CLE (ICLE, 65 patients), from 13 European countries were collected and statistically analyzed by an SPSS database. The main outcome measures included gender, age at onset of disease, LE-specific and LE-nonspecific skin lesions, photosensi…

AdultMalemedicine.medical_specialtyPathologyDatabases FactualAnti-nuclear antibodyCross-sectional studyImmunologyDiseaseDiagnosis Differential030207 dermatology & venereal diseases03 medical and health sciencesSex Factors0302 clinical medicineSurveys and QuestionnairesInternal medicineLupus Erythematosus CutaneousmedicineHumansImmunology and AllergyProspective StudiesAge of OnsetGeography MedicalProspective cohort studyAgedSkin030203 arthritis & rheumatologyAutoimmune diseaseLupus erythematosusbusiness.industryfungiAge FactorsMiddle Agedmedicine.diseaseDermatologyRheumatology3. Good healthEuropeCross-Sectional StudiesFemaleAge of onsetbusinessAutoimmunity Reviews
researchProduct

Autoimmune findings resembling connective tissue disease in a patient with Castleman's disease.

1997

Multicentric angiofollicular lymphnode hyperplasia (multicentric Castleman's disease) may be associated with acute phase reaction and several autoimmune features. Since lymphadenopathy is a common feature in connective tissue disease, a clear distinction between the different disease entities may be difficult. We describe a 26-year-old male patient with predominant cervical lymphadenopathy, hepatosplenomegaly and polyserositis, diagnosed as collagen disease. He showed several autoimmune features including autoimmune haemolytic anaemia, cryoglobulinaemia, positive antinuclear and anti smooth muscle antibodies, serum immune complexes and a sensorimotor polyneuropathy. Under immunosuppressive …

AdultMalemedicine.medical_specialtyPathologyHepatosplenomegalyAutoimmune DiseasesDiagnosis DifferentialRheumatologyCervical lymphadenopathyInternal medicinemedicineHumansAge of OnsetConnective Tissue DiseasesPOEMS syndromeCollagen diseasebusiness.industryCastleman DiseaseBiopsy NeedleGeneral Medicinemedicine.diseaseConnective tissue diseaseRheumatologyPrednisolonemedicine.symptomDifferential diagnosisbusinessmedicine.drugClinical rheumatology
researchProduct

MRS SHOWS ABNORMALITIES BEFORE SYMPTOMS IN FAMILIAL ALZHEIMER DISEASE

2006

Background: Pathologic change in Alzheimer disease (AD) begins some years before symptoms. MRS has the potential to detect metabolic abnormalities reflecting this early pathologic change. Presenilin 1 (PS1) and amyloid precursor protein (APP) mutation carriers have a nearly 100% risk of developing AD and may be studied prior to symptom onset. Methods: Short echo time proton MR spectra were acquired from a midline posterior cingulate voxel in presymptomatic carriers of PS1 or APP mutations (“presymptomatic mutation carriers” [PMCs]; n = 7) and age- and sex-matched control subjects (n = 6). Ratios of N-acetyl aspartate (NAA), myo-inositol (MI), and choline-containing compounds (Cho) to creati…

AdultMalemedicine.medical_specialtyPathologyMagnetic Resonance SpectroscopyAlzheimer disease brain metabolism nuclear magnetic resonance spectroscopyAdolescentNeuropsychological TestsCreatineGastroenterologyPresenilinCentral nervous system diseasechemistry.chemical_compoundDegenerative diseaseAlzheimer DiseaseReference ValuesInternal medicinemental disordersmedicineHumansFamilySymptom onsetAge of OnsetChildSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaBrainInfantMiddle Agedmedicine.diseaseControl subjectsnervous system diseasesnervous systemchemistryChild PreschoolCarrier StateFemaleNeurology (clinical)Alzheimer's diseaseGeometric meanPsychology
researchProduct